TroFuse-011 study design: sacituzumab tirumotecan with or without pembrolizumab for advanced triple-negative breast cancer with PD-L1 CPS [0.03%]
TroFuse-011研究设计：用于PD-L1 CPS阳性晚期三阴性乳腺癌的Sacituzumab Govitecan单药或联合Pembrolizumab治疗
Hope S Rugo,Peter Schmid,Javier Cortes et al.
Hope S Rugo et al.
Patients with advanced TNBC with PD-L1 CPS < 10 are typically treated with chemotherapy and experience poor outcomes. Sacituzumab tirumotecan (sac-TMT; MK-2870/SKB264) is a trophoblast cell-surface antigen 2 (TROP2)-directed antibody-drug c...
Treatment patterns in relapsed/refractory marginal zone lymphoma: real-world evidence from seven countries [0.03%]
七国复发/难治性边缘区淋巴瘤的治疗模式：真实世界证据
Harshali Patel,Lynn Huynh,Patrick Squires et al.
Harshali Patel et al.
Background: Given the rarity of marginal zone lymphoma (MZL), real-world data on relapsed/refractory (R/R) MZL are limited. Methods: Th...
Estimated cardiac deaths associated with treating chronic lymphocytic leukemia with ibrutinib versus zanubrutinib in the United States [0.03%]
估计的与使用伊布替尼和zanubrutinib治疗慢性淋巴细胞白血病相关的心脏病死亡率——基于美国患者的分析结果
Jennifer R Brown,Talha Munir,Andrew H Lipsky et al.
Jennifer R Brown et al.
Background: In the absence of real-world comparative studies of cardiac death risk, this study estimates the potential reduction in cardiac mortality associated with treating chronic lymphocytic leukemia (CLL) patients wi...
Real-world effectiveness of pembrolizumab for first-line treatment of metastatic non-small-cell lung cancer: a decade of evidence and experience [0.03%]
帕博利珠单抗一线治疗转移性非小细胞肺癌的现实世界疗效：十年证据和经验
Riddhi A Babel,Stephen V Liu,Tao Fan et al.
Riddhi A Babel et al.
Non-small cell lung cancer (NSCLC) remains a global burden, particularly due to late‑stage diagnosis. Immune checkpoint inhibitors (ICIs) for mNSCLC, including first-line (1L) pembrolizumab regimens, significantly improved survival for the...
Matching-adjusted indirect comparison of enzalutamide versus apalutamide with androgen-deprivation therapy in patients with metastatic hormone-sensitive prostate cancer [0.03%]
用于转移性激素敏感型前列腺癌患者的恩扎卢胺与阿帕鲁胺匹配调整的间接比较：与雄激素剥夺治疗相比
Arun A Azad,Bhavik J Pandya,Hemant Singh Bhadauria et al.
Arun A Azad et al.
Aims: To compare the efficacy of enzalutamide + androgen-deprivation therapy (ADT) versus apalutamide + ADT in metastatic hormone-sensitive prostate cancer (mHSPC) using a matching-adjusted indirect comparison (MAIC). ...
Correction [0.03%]
改正
Published Erratum
Future oncology (London, England). 2026 Jul 27:1. DOI:10.1080/14796694.2026.2710455 2026
Management of high-risk non-muscle invasive bladder cancer: a real-world study in North America, Europe and Japan [0.03%]
高危非肌层浸润性膀胱癌的管理：北美、欧洲和日本的真实世界研究
Jens Bedke,Anthony Eccleston,Mia Unsworth et al.
Jens Bedke et al.
Introduction: Non-muscle-invasive bladder cancer (NMIBC) accounts for approximately 75% of newly diagnosed bladder cancers and is particularly prevalent in men. Guidelines stratify patients into risk categories based on d...
Efficacy analysis of first-line chemoimmunotherapy with or without radiotherapy in stage IVB esophageal squamous cell carcinoma: a real-world study [0.03%]
一线化疗免疫治疗联合或不联合放疗治疗IVB期食管鳞癌的疗效分析：一项真实世界研究
Yanhui Zhang,Yuqin Jin,Ruidan Zhang et al.
Yanhui Zhang et al.
Background: This study assessed whether adding radiotherapy (RT) to first-line chemoimmunotherapy (ICT) improves outcomes in stage IVB esophageal squamous cell carcinoma (ESCC), given the limited benefit of ICT alone. ...
Lipid biomarkers of prostate cancer: insights from triglycerides and saturated fatty acid metabolism [0.03%]
前列腺癌的脂质生物标志物：来自三酰甘油和饱和脂肪酸代谢的启示
Jia Wei He,Pei Zhen Li
Jia Wei He
Background: Prostate cancer poses a substantial threat to men's health. Previous studies have hinted at potential links between dietary components like lipids and saturated fatty acids (SFAs) and prostate cancer, yet the ...
Bridging the gap: clinical practice, guidelines, reimbursement and real-world challenges in breast imaging - webinar highlights [0.03%]
沟通的桥梁：临床实践、指南、报销与乳腺影像检查中的现实世界挑战-网络研讨会要点总结
Joana Reis,Amy K Patel,Maria Lopes et al.
Joana Reis et al.
Breast cancer is a leading cause of cancer-related mortality globally. Mammographic breast density is an identified independent risk factor to develop breast cancer. Nationwide breast cancer screening programs, which typically utilize X-ray...